Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, discusses his partnership with Sema4 and LabCorp and their joint goal to advance whole-exome sequencing (WES) for targeted oncology treatment.
Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, discusses his partnership with Sema4 and LabCorp and their joint goal to advance whole-exome sequencing (WES) for targeted oncology treatment.
His abstract, “Social Determinants of Health in a Prospective Study of Whole-Exome Sequencing in Advanced Cancer Patients From Underserved Communities,” is being presented at this year’s American Society of Clinical Oncology Annual Meeting.
Transcript
How do you hope to advance WES in the community oncology setting to address genomic testing disparities?
We submitted a few abstracts, and one of them was actually the whole-exome sequencing. I started talking about disparity with all of my lab partners, and 2 big labs—Sema4 and LabCorp—they both came on board to start helping us out, working with patients so that if patients cannot pay for the sequencing, we would let go of their out-of-pocket costs to make sure that patients do not feel discriminated if they don’t have resources for being sequenced and typed.
And with 2 companies, Sema4 and LabCorp, we started doing NGS [next-generation sequencing] and whole-exome sequencing. We found, really, the mutations that are actionable that would make a difference in the patient’s treatment. The studies are ongoing. We started this study by reaching out to, again, leadership. We convinced them that there’s a lack of reflection of the minority patient population in the global genomic database, something called genome-wide association studies, where 80% of the database is Northern Europeans, only 2% Black, 1% are Hispanic.
These 2 companies have provided us with the research tools, with the sole purpose of addressing disparities in the genomic testing. The first phase started at my clinic; we satisfactorily fulfilled all of the requirements. So now we are expanding that study to about 5 sites in Sema4 and 10 sites in the LabCorp study.
I do believe that appropriate representation of population genomics is a key to the success of precision medicine initiatives.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More